United States - English - NLM (National Library of Medicine)

akorn, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 5 mg in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. for prophylaxis of ophthalmia neonatorum due to n. gonorrhoeae or c. trachomatis . the effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing n.gonorrhoeae is not established. for infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin g should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. topical prophylaxis alone is inadequate for these infants. this drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - erythromycin 30 mg in 1 g - erythromycin and benzoyl peroxide topical gel usp is indicated for the topical treatment of acne vulgaris. erythromycin and benzoyl peroxide topical gel usp is contraindicated in those individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg in 1 ml - erythromycin topical solution usp, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical solution usp, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - erythromycin - gastro-resistant tablet - 250mg

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ccd animal health pty ltd - erythromycin as the thiocyanate - oral powder, pre-mix - erythromycin as the thiocyanate antibiotic active 750.0 mg/g - antibiotic & related - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - cholera | chronic respiratory disease complex | coryza | erythromycin susceptible infections | infectious coryza

United States - English - NLM (National Library of Medicine)

carilion materials management - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, usp and other antibacterial drugs, erythromycin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations

United States - English - NLM (National Library of Medicine)

a-s medication solutions - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, usp and other antibacterial drugs, erythromycin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations

United States - English - NLM (National Library of Medicine)

e. fougera & co. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - solution - 20 mg - erythromycin pledgets, usp are indicated for the topical treatment of acne vulgaris. erythromycin pledgets, usp are contraindicated in those individuals who have shown hypersensitivity to any of its components.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - erythromycin - gastro-resistant tablet - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbott laboratories ltd - erythromycin - gastro-resistant tablet - 250mg